CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:00 a.m. ET on Thursday, March 4, 2021, to discuss its fourth quarter and full year 2020 financial results and provide a business update.
The webcast of the conference call may be accessed by visiting the “Events” section in the Investor Relations page of the Wave Life Sciences website at www.wavelifesciences.com. The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 6269069. Following the conference call, an archived version of the call will be available on the website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development…
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75%…
Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers.New…
NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem RALEIGH, N.C., June…
MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…